Preventive Vaccines Market Synopsis:
Preventive Vaccines Market Size Was Valued at USD 75 Billion in 2023, and is Projected to Reach USD 106.7 Billion by 2032, Growing at a CAGR of 4% From 2024-2032.
The Preventive Vaccines Market analyses the global market of vaccines destined to prevent rather than to treat or cure diseases, focusing on the Infectious and Communicable Diseases category. These vaccines which are expected to stimulate immune reactions that will prevent people’s infection with diseases are critical in the reduction of morbidity/mortality worldwide. This market comprises of various types of vaccines to diseases such as flu, measles, hepatitis, polio, HPV and other diseases in future. Preventive vaccines are required by governments, public health organizations, and growing knowledge of immunization’s importance in medicine.
This industry has expanded over the course of the recent decades and this is due to several reasons such as the augment of the preventive vaccines consciousness, progress of the vaccines and increase of the diseases prevention. This has made different countries to prioritized immunization especially in areas that the major infection diseases are prevalent. The market is growing vastly since governments and various health organizations pump a lot of capital towards vaccination. This market emerges with the COVID-19 pandemic which introduced historical levels of focus and investment to vaccine creation and delivery. Availability of COVID-19 vaccine has raised the bar for new and effective preventive vaccines in other disease segments by creating more emphasis on research and development coupled with synergistic partnership between pharma firms and health organizations all over the world.
Furthermore, growing markets are the emerging markets that are implementing more rigorous immunization programs, and the one that is brought about by increased life expectancy in developed countries requiring more vaccines for diseases that are more prevalent in the elderly. Business entities are dedicating large resources towards developing new vaccines especially those that are high efficiency and have low side effects to fitting these demands. Thanks to the growth in the global physical infrastructure of cold chains, its performance in the distribution of vaccines has also increased, which positively influenced the growth in the market.
Preventive Vaccines Market Trend Analysis:
RNA Vaccines Revolutionize Preventive Medicine
- An important fact about the trends operating in the Preventive Vaccines Market is that mRNA vaccine technology is being implemented very actively. Now that COVID-19 mRNA vaccines have been shown to be possible, the writers argue that the pharmaceutical industry has realized that mRNA can reduce the time necessary to develop vaccines for new diseases. This method has been shown to be not only effective but also much more malleable than conventional vaccines, creating the possibility for the same vaccine platform to be developed rapidly to tackle other similarly erosive diseases such as influenza, Zika and HIV.
- This is promoting companies to get into mRNA technology platforms and improving work in other novel classes of vaccines including viral vector and protein subunit vaccines. Current big-pharma, particularly, is working with biotech companies to establish such innovative solutions, while government spending is shifting gradually to concentrate on the creation of effective mRNA … Over the course of its development, it may have a significant and sustainable effect on the Preventive Vaccines Market, allowing for the utilization of innovation methods, that can be both safer and more effective for the treatment of numerous vital infectious diseases at a quicker pace and or at a decreased cost.
Expanding Immunization Coverage in Low-Income Regions
- A great market development opportunity in Preventive Vaccines Market is the usage increase in the rates of vaccination in LMIC nations. However, at present, many LMICs are not able to acquire vaccines due to infrastructure and economic issues which have progresses at the global level. Based on their current efforts, the World Health Organisation (WHO) together with organisations like the Gavi, the Vaccine Alliance will continue to seek ways in which immunisation coverage can be enhanced through funding, educating the public as well as supplying immunisation kits. Increased immunization of those groups of population who have limited immunity will not only prevent millions of deaths, but also contribute toward development of various markets for specific vaccines.
Preventive Vaccines Market Segment Analysis:
Preventive Vaccines Market is Segmented on the basis of Type, Disease, and Region
By Type, Inactivated Vaccines segment is expected to dominate the market during the forecast period
- The market for Preventive Vaccines is segmented based on product as Inactivated Vaccines, which is predicted to lead the segment during the forecast period as these vaccines are quite popular due to their capability to prevent various infectious diseases. Immunization with whole organism vaccines that are inactivated or attenuated is possible due to their safe and stable nature which makes them easily usable during the nationwide campaigns. These vaccines have no potential of causing the diseases they prevent; hence they encourage people to use them. Furthermore, the stability of inactivated vaccines at standard refrigeration temperature enhances their availability more so in developing nations with poor cold chain facilities. Therefore, it will continue to be applied to the prevention and control of diseases such as poliomyelitis, hepatitis A, and influenza – this factor will give the segment the strongest impetus to growth in the global market.
By Disease, Pneumococcal segment expected to held the largest share
- The Pneumococcal vaccine segment would have the largest market share in the Preventive Vaccines Market during the forecast period owing to a high incidence of pneumococcal diseases globally: pneumonia, meningitis, and sepsis majoring in children, elderly individuals, and immunocompromised people.. Lately it has emerged that pneumococcal vaccines reduce these severe infections significantly, and these vaccines have become major staples of immunization initiatives around the world. Due to the rising popularity of pneumococcal vaccination particularly for at risk groups and the expansion of vaccination services in the emerging nations, there is a number of optimistic outlooks of pneumococcal vaccines market. Such a requirement, working in conjunction with improving methods of developing the sophisticated structure of new vaccines that afford broader immunity, accounts for the segment’s market leadership.
Preventive Vaccines Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- North America led The Preventive Vaccines Market in 2023 due to factors such as sound health care systems, enhanced government support towards the immunization programs and sound knowledge among the masses in regards to preventive vaccines. Among the countries, the United States dominates this market mainly because of the higher research intensity, higher healthcare expenditure, and the larger support it provides to vaccination campaigns. According to industry reports in 2021, North America accounts for more than 35% of the shares of preventive vaccines as it continues to extend its efforts to provide better access to vaccines on COVID-19 and other diseases across the globe.
Active Key Players in the Preventive Vaccines Market:
- AstraZeneca plc (UK)
- Bavarian Nordic A/S (Denmark)
- Bharat Biotech (India)
- CSL Limited (Australia)
- Daiichi Sankyo Company, Limited (Japan)
- Emergent BioSolutions Inc. (USA)
- GlaxoSmithKline plc (UK)
- Johnson & Johnson (USA)
- Merck & Co., Inc. (USA)
- Moderna, Inc. (USA)
- Novavax, Inc. (USA)
- Pfizer Inc. (USA)
- Sanofi S.A. (France)
- Serum Institute of India Pvt. Ltd. (India)
- Sinovac Biotech Ltd. (China)
- Other Active Players
Key Industry Developments in the Preventive Vaccines Market:
- In April 2024, A partnership was formed between Bharat Biotech and Bilthoven Biologicals B.V. to manufacture and distribute oral polio vaccinations.
- In April 2024, VBI Vaccines Inc. increased the scope of its strategic partnership with the Canadian government to expedite the development of a patented MLE platform and enveloped virus-like particle.
|
Preventive Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 75 Billion |
|
Forecast Period 2024-32 CAGR: |
4 % |
Market Size in 2032: |
USD 106.7 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Preventive Vaccines Market by Type
4.1 Preventive Vaccines Market Snapshot and Growth Engine
4.2 Preventive Vaccines Market Overview
4.3 Live/Attenuated Vaccines
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Live/Attenuated Vaccines: Geographic Segmentation Analysis
4.4 Inactivated Vaccines
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Inactivated Vaccines: Geographic Segmentation Analysis
4.5 Subunit Vaccines
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Subunit Vaccines: Geographic Segmentation Analysis
4.6 Toxoid Vaccines
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Toxoid Vaccines: Geographic Segmentation Analysis
4.7 MRNA Vaccines
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 MRNA Vaccines: Geographic Segmentation Analysis
4.8 and Other Vaccine Types
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 and Other Vaccine Types: Geographic Segmentation Analysis
Chapter 5: Preventive Vaccines Market by Disease Type
5.1 Preventive Vaccines Market Snapshot and Growth Engine
5.2 Preventive Vaccines Market Overview
5.3 Pneumococcal
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Pneumococcal: Geographic Segmentation Analysis
5.4 Poliovirus
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Poliovirus: Geographic Segmentation Analysis
5.5 Hepatitis
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Hepatitis: Geographic Segmentation Analysis
5.6 Influenza
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Influenza: Geographic Segmentation Analysis
5.7 Measles
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Measles: Geographic Segmentation Analysis
5.8 Mumps
5.8.1 Introduction and Market Overview
5.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.8.3 Key Market Trends, Growth Factors and Opportunities
5.8.4 Mumps: Geographic Segmentation Analysis
5.9 and Rubella (MMR)
5.9.1 Introduction and Market Overview
5.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.9.3 Key Market Trends, Growth Factors and Opportunities
5.9.4 and Rubella (MMR): Geographic Segmentation Analysis
5.10 COVID-19
5.10.1 Introduction and Market Overview
5.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.10.3 Key Market Trends, Growth Factors and Opportunities
5.10.4 COVID-19: Geographic Segmentation Analysis
5.11 and Other Disease Types
5.11.1 Introduction and Market Overview
5.11.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.11.3 Key Market Trends, Growth Factors and Opportunities
5.11.4 and Other Disease Types: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Preventive Vaccines Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ASTRAZENECA PLC (UK)
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BAVARIAN NORDIC A/S (DENMARK)
6.4 BHARAT BIOTECH (INDIA)
6.5 CSL LIMITED (AUSTRALIA)
6.6 DAIICHI SANKYO COMPANY
6.7 LIMITED (JAPAN)
6.8 EMERGENT BIOSOLUTIONS INC. (USA)
6.9 GLAXOSMITHKLINE PLC (UK)
6.10 JOHNSON & JOHNSON (USA)
6.11 MERCK & CO. INC. (USA)
6.12 MODERNA INC. (USA)
6.13 NOVAVAX INC. (USA)
6.14 PFIZER INC. (USA)
6.15 SANOFI S.A. (FRANCE)
6.16 SERUM INSTITUTE OF INDIA PVT. LTD. (INDIA)
6.17 SINOVAC BIOTECH LTD. (CHINA)
6.18 OTHER ACTIVE PLAYERS
Chapter 7: Global Preventive Vaccines Market By Region
7.1 Overview
7.2. North America Preventive Vaccines Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Live/Attenuated Vaccines
7.2.4.2 Inactivated Vaccines
7.2.4.3 Subunit Vaccines
7.2.4.4 Toxoid Vaccines
7.2.4.5 MRNA Vaccines
7.2.4.6 and Other Vaccine Types
7.2.5 Historic and Forecasted Market Size By Disease Type
7.2.5.1 Pneumococcal
7.2.5.2 Poliovirus
7.2.5.3 Hepatitis
7.2.5.4 Influenza
7.2.5.5 Measles
7.2.5.6 Mumps
7.2.5.7 and Rubella (MMR)
7.2.5.8 COVID-19
7.2.5.9 and Other Disease Types
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Preventive Vaccines Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Live/Attenuated Vaccines
7.3.4.2 Inactivated Vaccines
7.3.4.3 Subunit Vaccines
7.3.4.4 Toxoid Vaccines
7.3.4.5 MRNA Vaccines
7.3.4.6 and Other Vaccine Types
7.3.5 Historic and Forecasted Market Size By Disease Type
7.3.5.1 Pneumococcal
7.3.5.2 Poliovirus
7.3.5.3 Hepatitis
7.3.5.4 Influenza
7.3.5.5 Measles
7.3.5.6 Mumps
7.3.5.7 and Rubella (MMR)
7.3.5.8 COVID-19
7.3.5.9 and Other Disease Types
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Russia
7.3.6.2 Bulgaria
7.3.6.3 The Czech Republic
7.3.6.4 Hungary
7.3.6.5 Poland
7.3.6.6 Romania
7.3.6.7 Rest of Eastern Europe
7.4. Western Europe Preventive Vaccines Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Live/Attenuated Vaccines
7.4.4.2 Inactivated Vaccines
7.4.4.3 Subunit Vaccines
7.4.4.4 Toxoid Vaccines
7.4.4.5 MRNA Vaccines
7.4.4.6 and Other Vaccine Types
7.4.5 Historic and Forecasted Market Size By Disease Type
7.4.5.1 Pneumococcal
7.4.5.2 Poliovirus
7.4.5.3 Hepatitis
7.4.5.4 Influenza
7.4.5.5 Measles
7.4.5.6 Mumps
7.4.5.7 and Rubella (MMR)
7.4.5.8 COVID-19
7.4.5.9 and Other Disease Types
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 The Netherlands
7.4.6.5 Italy
7.4.6.6 Spain
7.4.6.7 Rest of Western Europe
7.5. Asia Pacific Preventive Vaccines Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Live/Attenuated Vaccines
7.5.4.2 Inactivated Vaccines
7.5.4.3 Subunit Vaccines
7.5.4.4 Toxoid Vaccines
7.5.4.5 MRNA Vaccines
7.5.4.6 and Other Vaccine Types
7.5.5 Historic and Forecasted Market Size By Disease Type
7.5.5.1 Pneumococcal
7.5.5.2 Poliovirus
7.5.5.3 Hepatitis
7.5.5.4 Influenza
7.5.5.5 Measles
7.5.5.6 Mumps
7.5.5.7 and Rubella (MMR)
7.5.5.8 COVID-19
7.5.5.9 and Other Disease Types
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Preventive Vaccines Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Live/Attenuated Vaccines
7.6.4.2 Inactivated Vaccines
7.6.4.3 Subunit Vaccines
7.6.4.4 Toxoid Vaccines
7.6.4.5 MRNA Vaccines
7.6.4.6 and Other Vaccine Types
7.6.5 Historic and Forecasted Market Size By Disease Type
7.6.5.1 Pneumococcal
7.6.5.2 Poliovirus
7.6.5.3 Hepatitis
7.6.5.4 Influenza
7.6.5.5 Measles
7.6.5.6 Mumps
7.6.5.7 and Rubella (MMR)
7.6.5.8 COVID-19
7.6.5.9 and Other Disease Types
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkiye
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Preventive Vaccines Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Live/Attenuated Vaccines
7.7.4.2 Inactivated Vaccines
7.7.4.3 Subunit Vaccines
7.7.4.4 Toxoid Vaccines
7.7.4.5 MRNA Vaccines
7.7.4.6 and Other Vaccine Types
7.7.5 Historic and Forecasted Market Size By Disease Type
7.7.5.1 Pneumococcal
7.7.5.2 Poliovirus
7.7.5.3 Hepatitis
7.7.5.4 Influenza
7.7.5.5 Measles
7.7.5.6 Mumps
7.7.5.7 and Rubella (MMR)
7.7.5.8 COVID-19
7.7.5.9 and Other Disease Types
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
|
Preventive Vaccines Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 75 Billion |
|
Forecast Period 2024-32 CAGR: |
4 % |
Market Size in 2032: |
USD 106.7 Billion |
|
Segments Covered: |
By Type |
|
|
|
By Application |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
